Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Introduction to the China Clinical Trials Landscape with Andy Benson
Deep dive into China’s clinical landscape to learn more about the startling growth in clinical research in our whitepaper from Dr Annie Siu, PhD, MBA, APAC - Content Director, Informa Pharma Intelligence and Andrew Benson, MSc - Senior Director, Trialtrove.
China Clinical Trials Landscape
In 2017, Informa Pharma Intelligence took a deep dive into the clinical trial landscape in China over the previous 10 years, in a whitepaper entitled “Is China the Dark Horse in Clinical Development?”. That analysis showed that the number of trial starts in China had been trending upwards year-on-year and suggested that China was on course to become a formidable player within the pharma industry on a global stage.
In this new analysis we return to this topic to see how the dynamics of the clinical trial landscape in China evolved in the intervening five years, and whether the upward trajectory has been maintained.
The landscape of clinical trials continues to evolve over time as scientific breakthroughs and technological innovations emerge, which continue to be tracked by assessing recently initiated trials through Trialtrove’s annual Clinical Trials Roundup. Assessing the landscape of Phase I–III clinical trials that initiated in the previous year provides insights into competitive trial landscape, revealing priorities and strategies of the industry at large, as well as individual company’s performance.